- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Pharma Pulse 7/1/24: AI Frenzy Propels Stocks to Monster First Half, Considerations for Integrating Artificial Intelligence & more
The latest news for pharma industry insiders.
Considerations for Integrating Artificial Intelligence
In part 4 of this video interview, Diane Lacroix, vice president, clinical data management, eClinical Solutions discusses what industry stakeholders should be keeping top of mind when integrating AI into their workflows.
Healthcare Takes Backseat in Biden-Trump Debate. Biden's Age Not So Much
The presidential candidates didn't spend a lot of time talking about healthcare issues last night, but Democrats are concerned about Biden's performance, especially in the early going.
AI Frenzy Propels Stocks to Monster First Half
S&P 500 has climbed 15% despite reduced hopes for Federal Reserve interest-rate cuts.
Global mRNA Cancer Vaccines Clinical Trials & Future Market Outlook 2024 - ResearchAndMarkets.com
The "Global mRNA Cancer Vaccines Clinical Trials & Market Future Outlook 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.
Global mRNA Cancer Vaccines Clinical Trials & Future Market Outlook 2024 Report Highlights:
- mRNA Cancer Vaccines in Clinical Trials: > 60 Vaccines
- Highest Phase of Clinical Trials: Phase III (2 Vaccine)
- mRNA Cancer Vaccine Clinical Trials Insight by Company, Country, Indication & Phase
- First Commercial mRNA Vaccine Approval Expected by 2029
- US & China Dominating mRNA Cancer Vaccines Clinical Trials: > 45 Vaccines
- mRNA Vaccines for Skin Cancer Dominating Trials: > 10 Vaccines
The future of clinical research focuses on sustainability and patient-centricity. Discover key considerations for greener supply chain management in this piece from @Clin_Trials : https://ow.ly/oYMj50Sq0Ms
Have news you want us to share in Pharma Pulse? Reach out to Social
Media Editor Miranda Schmalfuhs
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
